interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Dordaviprone Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Dordaviprone Hydrochloride, and who makes it?

Dordaviprone Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Dordaviprone Hydrochloride1 dosage-form group in the Orange Book
0generic makers listed
  1. Dordaviprone Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Modeyso. No generic is listed as marketed.

2020202520302035204001brand 2025data datePatent 9629842 listed to expire 30 April 2032Patent RE46290 listed to expire 30 August 2032Patent 9265765 listed to expire 26 July 2034Patent 11976068 listed to expire 1 March 2036Patent 12102639 listed to expire 30 January 2037Patent 10369154 listed to expire 30 January 2037Patent 10172862 listed to expire 30 January 2037Exclusivity NCE to 6 August 2030Exclusivity ODE-547 to 6 August 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 6 August 2030Exclusivity NCE Modeyso
  • 6 August 2032Exclusivity ODE-547 Modeyso
  • 30 April 2032Patent 9629842
  • 30 August 2032Patent RE46290
  • 26 July 2034Patent 9265765 drug product
  • 1 March 2036Patent 11976068 drug product
  • 30 January 2037Patent 12102639
  • 30 January 2037Patent 10369154
  • 30 January 2037Patent 10172862

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.